1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Valneva Rebounds From 2022 Setbacks With Pivotal Success For Chikungunya Jab

 
• By Ayisha Sharma

The French firm’s vaccine candidate, VLA1553, has passed a Phase III milestone for the mosquito-borne disease – which has no approved options – as it bounces back from a year full of COVID-19-related disappointments.  

mosquito on skin
The Mosquitoes That Spread Chikungunya Are Moving Into New Areas • Source: Shutterstock
Key Takeaways:

  • VLA1553 produced protective antibody levels in 99% of subjects after a single dose.

Valneva SE’s chikungunya vaccine candidate, VLA1553, has succeeded in a Phase III trial, boding well for filings submitted in the US and Canada as the firm leaves behind its COVID-19 related woes in 2022.

Chikungunya is a mosquito-borne viral disease endemic in some parts of Africa, Asia and the Americas. Symptoms include fever, headaches,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.

More from R&D

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.